Achieving reliable and scalable lentiviral vector production
Sponsor
Developing stable lentiviral vector producer cell lines is a time-consuming and labor-intensive process, often taking a year or more to fully develop and characterize the cell line development platform. Due to the complexity of the work, many market-available systems ultimately fail to meet the needs of commercial manufacturing due to issues such as toxigenic titer, cell line stability, and culture adaptation.
EurekaBio has developed its proprietary EuLV® system, which can deliver stable LVV HEK293T producer cell lines in as short a time period as 5 months. The EuLV® system has irreplaceable advantages in terms of process reliability, scale-up capability, production cost, and virus product safety. The potential to achieve high-titer lentiviral vector manufacture using this platform will be explored in this webinar using a real-world case study.
Join us for a webinar on ways to address the pressing need for a reliable and scalable lentiviral vector manufacturing solution.
- What is the EuLV stable producer cell line development platform
- How to develop lentiviral vector producer cell lines using the EuLV platform
- What is the EuBioX - an automated monoclonal screening platform
- A real-world case study of a reliable and scalable LVV production workflow
SPEAKERS
You might also like
Same-section spatial multiomics: a platform for detailed analysis of the solid tumor TME
Precision in production: optimizing monitoring and quality control for high-value plasmids
Advancing cell therapy: innovations in polymer-based encapsulation and delivery
Pure and simple: understanding LNP analytics for better mRNA-based drugs
